CN109563073B - 用于治疗对5-ht1a受体控制的血清素能调节敏感的疾病的化合物 - Google Patents

用于治疗对5-ht1a受体控制的血清素能调节敏感的疾病的化合物 Download PDF

Info

Publication number
CN109563073B
CN109563073B CN201780038390.3A CN201780038390A CN109563073B CN 109563073 B CN109563073 B CN 109563073B CN 201780038390 A CN201780038390 A CN 201780038390A CN 109563073 B CN109563073 B CN 109563073B
Authority
CN
China
Prior art keywords
compound
iib
nmr
cdcl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780038390.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563073A (zh
Inventor
J·尼奇科夫斯卡
A·布茨基
A·纽曼－坦克雷迪
M·A·瓦尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Jagellonne
Neurolixis
Original Assignee
Universite Jagellonne
Neurolixis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Jagellonne, Neurolixis filed Critical Universite Jagellonne
Publication of CN109563073A publication Critical patent/CN109563073A/zh
Application granted granted Critical
Publication of CN109563073B publication Critical patent/CN109563073B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
CN201780038390.3A 2016-06-24 2017-06-23 用于治疗对5-ht1a受体控制的血清素能调节敏感的疾病的化合物 Active CN109563073B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305769.8A EP3260452A1 (en) 2016-06-24 2016-06-24 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
EP16305769.8 2016-06-24
PCT/EP2017/065585 WO2017220799A1 (en) 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors

Publications (2)

Publication Number Publication Date
CN109563073A CN109563073A (zh) 2019-04-02
CN109563073B true CN109563073B (zh) 2021-12-07

Family

ID=56404042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780038390.3A Active CN109563073B (zh) 2016-06-24 2017-06-23 用于治疗对5-ht1a受体控制的血清素能调节敏感的疾病的化合物

Country Status (9)

Country Link
US (1) US10562853B2 (https=)
EP (2) EP3260452A1 (https=)
JP (1) JP6935873B2 (https=)
CN (1) CN109563073B (https=)
AU (1) AU2017281742B2 (https=)
CA (1) CA3028036A1 (https=)
DK (1) DK3475268T3 (https=)
ES (1) ES2831853T3 (https=)
WO (1) WO2017220799A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242772A (zh) * 1996-11-21 2000-01-26 皮埃尔法博赫药品公司 吡啶－2－基甲胺衍生物、其制备方法及其作为药物的用途
CN1325396A (zh) * 1998-10-09 2001-12-05 皮埃尔法博赫药品公司 作为5－ht1受体兴奋剂的芳基(4－氟－4－[(2－吡啶－2－基乙基氨基)甲基]－哌啶－1－基)甲酮衍生物
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702211B1 (fr) * 1993-03-04 1995-06-02 Pf Medicament Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique.
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242772A (zh) * 1996-11-21 2000-01-26 皮埃尔法博赫药品公司 吡啶－2－基甲胺衍生物、其制备方法及其作为药物的用途
CN1325396A (zh) * 1998-10-09 2001-12-05 皮埃尔法博赫药品公司 作为5－ht1受体兴奋剂的芳基(4－氟－4－[(2－吡啶－2－基乙基氨基)甲基]－哌啶－1－基)甲酮衍生物
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors;Bernard Vacher等;《J. Med. Chem.》;19980711;第41卷;第5070页introduction第1段，第5073页Table 1. *

Also Published As

Publication number Publication date
CN109563073A (zh) 2019-04-02
ES2831853T3 (es) 2021-06-09
EP3260452A1 (en) 2017-12-27
EP3475268B9 (en) 2021-04-21
DK3475268T3 (da) 2020-10-26
US20190194132A1 (en) 2019-06-27
JP2019519615A (ja) 2019-07-11
WO2017220799A1 (en) 2017-12-28
CA3028036A1 (en) 2017-12-28
EP3475268A1 (en) 2019-05-01
AU2017281742B2 (en) 2021-01-07
EP3475268B1 (en) 2020-08-19
US10562853B2 (en) 2020-02-18
JP6935873B2 (ja) 2021-09-15
AU2017281742A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
KR102041442B1 (ko) 중수소화된 디아미노피리미딘 화합물 및 이 화합물을 함유하는 약물 조성물
KR102072850B1 (ko) 브로모도메인 억제제로서의 벤즈이미다졸 유도체
JP5335932B2 (ja) 制癌剤である二置換ピリジン誘導体
KR20220141328A (ko) 소분자 sting 길항제
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
JP2022544714A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CN103717593B (zh) 调节激酶的组合物和方法
JP2004509893A (ja) 置換型アゼピノ［４，５ｂ］インドリン誘導体
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
AU2013253541A1 (en) Quinazolinedione derivative
CN117999265A (zh) 取代的融合双环大环化合物及其相关治疗方法
JP2019526577A (ja) イミダゾール誘導体及び自己免疫性疾患若しくは炎症性疾患又は癌の治療におけるそれらの使用
JP2017512796A (ja) 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用
EP3359531A1 (en) 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
KR102526281B1 (ko) 옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도
CN117651703A (zh) 取代的氨基甲酸大环化合物及其相关治疗方法
CN109563073B (zh) 用于治疗对5-ht1a受体控制的血清素能调节敏感的疾病的化合物
CN116507622B (zh) Gpr52调节剂化合物
KR20240046742A (ko) 소분자 sting 길항제
CA3211638A1 (en) New 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives as sigma ligands
EP3634409B1 (en) Orexin receptor antagonists
HK40007735A (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
HK40007735B (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
JP2023063270A (ja) ２－ヘテロアリールアミノキナゾリノン誘導体からなる医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant